Acquisitions and Divestitures - 2016 Acquisitions (Details) - USD ($) $ in Millions				1 Months Ended	6 Months Ended		9 Months Ended	12 Months Ended
	Aug. 02, 2016	Mar. 01, 2016	Jan. 22, 2016	May 31, 2015	Dec. 31, 2015	Dec. 27, 2014	Oct. 01, 2016	Dec. 31, 2016	Jun. 27, 2015	Jun. 28, 2014
Business Acquisition [Line Items]
Finite lived assets, useful life							20 years
Research and development					$ 88.2	$ 89.8		$ 184.0	$ 187.8	$ 152.5
Benzaclin
Business Acquisition [Line Items]
Effective date of acquisition	Aug. 02, 2016
Percentage of interest acquired	60.90%
Cash paid for acquisition	$ 62.0
Tretinoin Products
Business Acquisition [Line Items]
Effective date of acquisition			Jan. 22, 2016
Cash paid for acquisition			$ 416.4
Contingent consideration			$ 0.0
Development-Stage Rx Products
Business Acquisition [Line Items]
Effective date of acquisition		Mar. 01, 2016
Cash paid for acquisition		$ 0.0
Contingent consideration		$ 24.9
Distribution and license agreements, supply agreements | Benzaclin
Business Acquisition [Line Items]
Finite lived assets, useful life	9 years
Developed product technology, formulations, and product rights | Tretinoin Products
Business Acquisition [Line Items]
Finite lived assets, useful life			20 years
Non-compete agreements | Tretinoin Products
Business Acquisition [Line Items]
Finite lived assets, useful life			5 years
Contractual arrangement
Business Acquisition [Line Items]
Research and development				$ 18.0
Minimum | Development-Stage Rx Products
Business Acquisition [Line Items]
Royalty payment period		7 years
Maximum | Development-Stage Rx Products
Business Acquisition [Line Items]
Royalty payment period		10 years